Finnish VC Inventure invests $5M in Samphire Neuroscience to revolutionize female healthcare

Samphire Neuroscience, a pioneering company in women’s neurotechnology, has announced it has raised $5 million in a Series A funding round. This funding will enable the company to further develop and expand its flagship product, the Nettle brain device, aimed at alleviating menstrual symptoms. The funding round was led by Nordic venture capital firm Inventure VC, with additional support from US-based Fortify Ventures.

Investment details

• Inventure VC, a prominent venture capital firm based in Scandinavia, led the round. It specializes in backing innovative technology startups across Europe. In July 2024, it has invested in Valo.ai, a software development company developing an AI-native tool for Salesforce that uses automation in SaaS services to identify and remedy misconfigurations at their root.

• Their investment in Samphire underscores confidence in the company’s potential to revolutionize women’s health through neurotechnology. 

• Fortify Ventures, a US-based investor focused on advancing healthcare innovation, also joined the round.

About Samphire Neuroscience

• Founded in 2021 by neuroscientist Emilė Radytė and legal expert Alex Cook, Samphire Neuroscience aims to transform how menstrual and premenstrual symptoms are managed.

• The company’s flagship product, Nettle, is a CE-certified headband that uses transcranial direct current stimulation (tDCS) technology to target the mental and physical symptoms associated with menstruation. The device sold out twice during its pre-launch phase, reflecting robust demand for innovative neurotechnologies in the women’s health space.

• Worn for just 20 minutes daily, usually during the five days leading up to menstruation, Nettle offers a non-hormonal and medication-free alternative, addressing a significant unmet need in women’s health.

The funding will be pivotal in expanding Samphire’s commercial reach through partnerships with clinics and pilot programs, including collaboration with NHS-affiliated care centers across the UK. Moreover, the company plans to enhance its direct-to-consumer sales platform, making Nettle more accessible to users worldwide.